PharmaCielo Ltd. (V:PCLO*CA)
Business Focus: Alternative Medicine
Apr 10, 2024 07:45 am ET
PharmaCielo Signs Binding Letter of Intent to Acquire Operations in Thailand; Announces $2 Million Non-Brokered Private Placement with Participation from PharmaCielo Insiders and Siam Ventures Investo
The proposed acquisition of Siam Ventures, which provides contract manufacturing services through a subsidiary, will act as a gateway to large Asian markets for PharmaCielo product.
Mar 26, 2024 07:30 am ET
PharmaCielo to Supply Ease Labs with Commercial Shipments of API to Fulfill Contract with State Government of Sao Paulo, Brazil
Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - March 26, 2024) - PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) ("PharmaCielo" or the "Company"), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), and Ease Labs Pharma ("Ease Labs") a leading GMP-certified pharmaceutical company in Brazil specialized in developing, manufacturing, and distributing pharma-grade cannabis-based products, are pleased to announce that the pharmaceutical product "Cannabidiol Ease Labs 100mg/ml" (the "Product") owned and manufactured by Ease Labs in Brazil, has been selected by the State Government of São Paulo to be distributed as part of its new Public-Health Distribution Program (the "Program"). The Product is based on PharmaCielo's active pharmaceutical ingredient ("API").
Mar 01, 2024 07:30 am ET
Colombian Government Continues its Support of Domestic Cannabis Industry - Resolution Extending THC Inventory Allowance Provides Immediate Benefit to PharmaCielo
Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - March 1, 2024) - PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) ("PharmaCielo" or the "Company"), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), today commented on the recent decision by the Colombian Ministries of Health, Justice, and Agriculture (the "Ministries") to extend the timeframe within which THC products may be sold. The Ministries have passed a resolution allowing producers up to 48 months to sell these products following their production, compared to the original 24 months (the "Resolution"). This Resolution is of immediate benefit to the industry and to PharmaCielo. As the country's largest cannabis producer, PharmaCielo has over 2.0 tonnes of THC extract in inventory to support expected growth in international sales in the following years, which would have been subject to destruction under the legacy framework.
Jan 04, 2024 07:00 am ET
Benuvia and PharmaCielo Announce Strategic Partnership to Manufacture cGMP Pharmaceutical-Grade CBD Isolate and Related Products
Austin, Texas and Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - January 4, 2024) - Benuvia Operations, LLC ("Benuvia"), a FDA registered, DEA licensed and cGMP certified leader in pharmaceutical cannabinoids, and PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) ("PharmaCielo"), the Canadian parent of Colombia's premier cultivator, producer and global supplier of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), are thrilled to announce a strategic partnership to produce cGMP pharmaceutical-grade Active Pharmaceutical Ingredients ("APIs") for the global market, including Brazil, Australia, Europe and U.S.A. (the "Strategic Partnership").
Nov 29, 2023 07:30 am ET
PharmaCielo Announces Q3 2023 Financial Results
Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - November 29, 2023) - PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) ("PharmaCielo" or the "Company"), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., today announced financial results for the third quarter ended September 30, 2023.
Oct 06, 2023 07:40 am ET
PharmaCielo Raises $3.3 Million Under Previously Announced Non-Brokered Private Placement
Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - October 6, 2023) - PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) ("PharmaCielo" or the "Company"), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), today announced that it has closed another tranche of the non-brokered private placement (the "New Offering") that was announced on June 29, 2023. Under the New Offering, to date, PharmaCielo issued 3,900 debenture units (each a "Unit"), for aggregate proceeds of $3,300,000, while 600 Units have been issued to satisfy amounts owing to certain previous service providers and employees. The Company is continuing to issue the Units in multiple closings and using the proceeds from the sale of the Units for operations, working capital and the build-out of its international sales program.
Aug 29, 2023 07:45 am ET
PharmaCielo Announces Q2 2023 Financial Results
Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - August 29, 2023) - PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) ("PharmaCielo" or the "Company"), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., today announced financial results for the second quarter ended June 30, 2023.
Aug 10, 2023 07:45 am ET
PharmaCielo Provides Corporate Update
Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - August 10, 2023) - PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) ("PharmaCielo" or the "Company"), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), today provided shareholders with an update on several ongoing initiatives.
Jul 11, 2023 09:00 am ET
PharmaCielo Announces Appointment of Marc Lustig as Chairman and CEO
Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - July 11, 2023) - PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) ("PharmaCielo" or the "Company"), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), today announced that Marc Lustig has been appointed Chairman and CEO of PharmaCielo. Mr. Lustig has a proven history of value creation across the cannabis, capital markets and health sciences sectors. Mr. Bill Petron, the Company's current Chairman and CEO will remain on the Board as Lead Director.
Jun 29, 2023 07:30 am ET
PharmaCielo Provides Corporate Update
All amounts expressed in Canadian dollars unless otherwise noted
May 29, 2023 07:30 am ET
PharmaCielo Announces Q1 2023 Financial Results
Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - May 29, 2023) - PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) ("PharmaCielo" or the "Company"), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., today announced financial results for the first quarter ended March 31, 2023.
May 16, 2023 07:30 am ET
PharmaCielo Announces Shipment of Pharmaceutical Grade Cannabis Extract to Customer in South Africa
Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - May 16, 2023) - PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) ("PharmaCielo" or the "Company"), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), today announced that it has made an initial shipment of CBD Isolate to a specialty biotechnology company based in South Africa that specializes in offering GMP certified private label cannabinoid pharmaceutical products to customers in advanced medical cannabis markets globally, including the UK and Australia. PharmaCielo has shipped CBD Isolate as an API1 to facilitate pre-commercial testing prior to inclusion in the customer's private label products.
May 01, 2023 07:30 am ET
PharmaCielo Announces Financial Results for the Fourth Quarter and Fiscal Year Ended December 31, 2022
Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - May 1, 2023) - PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) ("PharmaCielo" or the "Company"), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., today announced financial results for the fourth quarter and year ended December 31, 2022.
Apr 19, 2023 07:30 am ET
PharmaCielo Announces Strategic Partnership with CANNPRISMA to Supply EU-GMP Certified Dried Flower to the European Medicinal Cannabis Market
Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - April 19, 2023) - PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) ("PharmaCielo" or the "Company"), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), today announced that it has partnered with CANNPRISMA - PHARMA, LDA ("CANNPRISMA"), a Portuguese Contract Manufacturing Organization ("CMO"), to supply high-quality EU-GMP1 certified medicinal cannabis flower to the European market. PharmaCielo will provide GACP2 flower to CANNPRISMA, which will convert the flower to EU-GMP standards and distribute it directly from Portugal to European customers. CANNPRISMA is a Portuguese medical cannabis company founded in 2018 that encompasses all aspects of the production process, from cultivation to distribution and research. The company's main objective is to provide high-quality medicinal cannabis products that comply with GACP and GMP standards, and serve as a reference in the market, ultimately contributing to enhancing the quality of life for as many people as possible.
Apr 14, 2023 10:15 pm ET
TSX Venture Exchange Stock Maintenance Bulletins
VANCOUVER, BC, April 14, 2023 /CNW/ -
Feb 08, 2023 06:30 am ET
PharmaCielo Receives Purchase Order for API from Brazilian Pharmaceutical Company - Represents Third Customer in the Country
PharmaCielo has received a purchase order for CBD Isolate as an API, which will be used by a large pharmaceutical company in Brazil (the "Customer"), for final testing.The Customer has already qualified PharmaCielo as a supplier of API – the Company expects to begin shipping product on a commercial basis to the Customer by Q4 2023.TORONTO and RIONEGRO, Colombia , Feb. 8, 2023 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo
Feb 02, 2023 06:30 am ET
PharmaCielo Announces Continued Progress on Efficiency Initiatives to Accelerate Profitability and Intention to Amend Warrant Terms
Steady progress against the efficiency plans initiated in mid-2021 with the transition to the current senior management team. Expects a reduction in its annualized fixed costs by approximately 25% compared to 2022 as a result of these ongoing efforts.The Company is focused on consistently reducing expenses and improving efficiency to facilitate a rapid transition to a cash flow positive position as its revenue continues to grow.Intends to amend the terms of 2,823,750 common share purchase Warrants, reducing the exercise price from C$1.44 to C$0.65 per Common Share.TORONTO and RIONEGRO, Colom
Jan 30, 2023 06:30 am ET
PharmaCielo Receives First Commercial Purchase Order from Ease Labs Pharma - Proprietary API a Key Ingredient in Recently Approved Product for Brazilian Market
Ease Labs Pharma, a global pharmaceutical company headquartered in Brazil, has received regulatory approval from the Brazilian Health Regulatory Agency (ANVISA) to launch its Canabidiol Ease Labs 100 mg/ml in Brazil beginning in January 2023, and PharmaCielo's proprietary API was included as part of that approval.PharmaCielo has been shipping product to Ease Labs since 2021 in support of its product development efforts. The Company has also made pre-commercial shipments of CBD full spectrum oil containing THC to Ease Labs beginning in June 2022, to support additional product development effo
Dec 05, 2022 06:45 am ET
PharmaCielo Announces First Shipment of Pharmaceutical Grade Cannabis Extract to Customer in Morocco
Represents PharmaCielo's first shipment to Africa. Morocco is pioneering the commercialization of cannabinoid products on the African continent and will be a growing market.The Company also announced that it has agreed to issue shares in settlement of certain interest payments and debt.TORONTO, Canada and RIONEGRO, Colombia, Dec. 5, 2022 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of dried cannabis flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Ho
Nov 22, 2022 01:59 pm ET
PharmaCielo Announces TSX Venture Exchange Approval of Warrant Extension
TORONTO and RIONEGRO, Colombia, Nov. 22, 2022 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO, OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of dried cannabis flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), today announced that the TSX Venture Exchange ("TSXV") has approved the extension of 9,007,200 warrants originally issued on November 20, 2020 (the "Warrants") under the TSX-Venture Symbol PCLO.WT. In accordance with the TSXV's rules for warrant amendments set out in section 3 of Poli
Oct 31, 2022 07:55 am ET
PharmaCielo Announces Q3 2022 Financial Results
In the first nine months of 2022, PharmaCielo has made shipments to 23 customers in nine countries, with continued growth expected for 2023.The Company has more than doubled Revenue to $3.8 million in the first nine months of 2022, compared to the first nine months of 2021.Consistent progress on streamlining the business, while investing in revenue-generating sales functions. SG&A expenses reduced by over 40% in the first nine months of 2022 vs. the same period in 2021, with further reductions expected.PharmaCielo's previously announced non-brokered private placement of debenture units w
Oct 12, 2022 07:45 am ET
PharmaCielo Announces Shipment of Pharmaceutical Grade Cannabis Extract to Customer in Uruguay
This is PharmaCielo's second pharmaceutical grade product shipment to a well-established Latin American pharmaceutical company with operations in Uruguay.TORONTO and RIONEGRO, Colombia, Oct. 12, 2022 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF) the Canadian parent of Colombia's premier cultivator and producer of dried cannabis flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), today announced that it has completed its second shipment of CBD Isolate to the Uruguayan subsidiary of a well-established Latin Am
Sep 15, 2022 07:55 am ET
PharmaCielo Announces Shipment of Dried Cannabis Flower to the Czech Republic, Representing the Company's First Shipment of Medicinal Grade Dried Cannabis Flower into the EU
Shipment made to an established pharmaceutical distributor and clinical research organization in the Czech Republic, focused on medicinal grade cannabinoidsTORONTO and RIONEGRO, Colombia, Sept. 15, 2022 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of dried cannabis flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), today announced that it has made its first shipment of THC-dominant dried cannabis flower to a customer in the Czech Republic,
Sep 14, 2022 07:55 am ET
PharmaCielo Announces Receipt of Production Quota of THC Dominant Dried Cannabis Flower for Export - Commercial Quantities of Flower Shipments to Begin in Early 2023
Colombian government has maintained its commitment to supporting its cannabis producers and building a dominant global export industry. Five tonne quota to grow THC-dominant cannabis strains for export as dried flower will support the fulfillment of current sales agreements, beginning in early 2023.TORONTO and RIONEGRO, Colombia, Sept. 14, 2022 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Hold
Aug 30, 2022 07:55 am ET
PharmaCielo Announces Q2 2022 Financial Results; Upsizes Oversubscribed Debenture Financing
The Company continues to grow sales and expects to build momentum through the remainder of 2022 and through 2023, with recent progress in Israel, Brazil and Mexico.PharmaCielo product has been sold in 14 countries to date, and the Company expects to increase this total to 17 countries by the end of 2022.PharmaCielo's previously announced non-brokered private placement of debenture units is oversubscribed for a total of $15.1 million issued or committed to date, with an aggregate of $7.1 million from management and directors of the Company.Recently received ICANN G.A.P and GACP certifications
Aug 25, 2022 07:55 am ET
PharmaCielo Announces Receipt of ICANN G.A.P and GACP Certifications, Opening Commercial Access to the Israeli Market
The Company expects to begin exporting dried flower to Israel in early 2023. Israel is one of the largest importers of medical cannabis in the world, with 109,352 active medical patients in 2021 (+35% vs. 2020)1.TORONTO and RIONEGRO, Colombia, Aug. 25, 2022 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), today announced it has received ICANN G.A.P and GACP certifications following the
Aug 04, 2022 07:30 am ET
PharmaCielo Announces First Shipment to Mexican Joint Venture Partner
The Company has made a pre-commercial shipment of CBD isolate to its Mexican joint venture, to support product development by a Mexican phytotherapeutic company.TORONTO and RIONEGRO, Colombia , Aug. 4, 2022 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), today announced its first shipment of cannabinoid products to its Mexican joint venture PharmaCielo S.A. de C.V. ("PharmaCielo Mexic
Jul 28, 2022 07:30 am ET
PharmaCielo Announces Sales Agreement with Brazilian Phyto-Therapeutic Customer, and Key Management and Board Appointments
TORONTO and RIONEGRO, Colombia , July 28, 2022 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), today announced a supply agreement (the "Agreement") with one of the largest phyto-therapeutic companies in the Brazilian market (the "Customer"). The Customer has an extensive distribution network across Latin America, and is also a certified B-Corp, reflecting its commitment to a transpare
Jun 06, 2022 07:30 am ET
PharmaCielo Announces Shipment of CBD Full Spectrum Oil to a Brazilian Pharmaceutical Customer
The Company has shipped pre-commercial quantities of CBD full spectrum oil containing THC, to support the development of a full spectrum product for the Brazilian market.TORONTO and RIONEGRO, Colombia, June 6, 2022 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), today announced an initial shipment of a CBD full spectrum extract with THC content to a well-established Brazilian Pharmace
May 30, 2022 07:55 am ET
PharmaCielo Announces Financial Results for the First Quarter Ended March 31, 2022
The Company expects Revenue to continue to grow – recently shipped 300 kg of CBD Full Spectrum Oil to a Spanish pharmaceutical company, announced entrance into Polish market, and shipments to Germany expected by late 2022. Steadily building pipeline in other key markets.Continued progress on streamlining the business, while continuing to invest in revenue-generating sales functions – SG&A expenses reduced by approximately 50% in Q1 2022 vs. Q1 2021, with further reductions expected.Expect to receive EU-GMP certification in the second half of 2022.All figures in Canadian dollars ($) unles
May 24, 2022 07:30 am ET
PharmaCielo Enters Spanish Market with Initial Shipment of 300 kg of CBD Full Spectrum Oil to Pharmaceutical Company
The Company has shipped pharmaceutical grade CBD full spectrum oil containing THC to Extractions Solutions SL, to support pre-commercial development of a full spectrum product for the European market.TORONTO and RIONEGRO, COLOMBIA, May 24, 2022 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), today announced that it has made an initial shipment of CBD full spectrum oil containing THC t
May 11, 2022 10:39 am ET
PharmaCielo Provides Update on Non-Brokered Private Placement of Debenture Units
TORONTO and RIONEGRO, Colombia, May 11, 2022 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), announces today that, further to its previously announced non-brokered private placement of debenture units ("Units"), it is engaged in ongoing discussions with specific parties and expects to issue up to an additional $3,500,000 principal amount of Units in the coming weeks, in one or more closings, subject t
May 06, 2022 07:30 am ET
PharmaCielo partners with Soteria Holdings Limited to license, import and wholesale its medical cannabis flower and extracts in the Polish market
Poland is one of the largest cannabis markets in Europe by patient population, with more than 28,000 prescriptions issued to approximately 10,000 patients in the first nine months of 20211.The Company expects to begin shipping to Poland during the first half of 2023.TORONTO and RIONEGRO, Colombia, May 6, 2022 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), today announced that it has
Apr 29, 2022 07:30 am ET
PharmaCielo Announces Financial Results for the Fourth Quarter and Fiscal Year Ended December 31, 2021
Regulation to enable dried flower export and expand applications of CBD-based products passed by the Colombian Government on February 22, 2022PharmaCielo's upstream and downstream scale and quality uniquely position the Company to be a dominant competitor with current suppliers of psychoactive flower to the EU and other markets.Executing on opportunities to streamline the business, while continuing to invest in revenue-generating sales functions – SG&A[i] expenses totaled $23.1 million in 2021 compared to $37.8 million in 2020.Currently working toward EU-GMP certification on top of the e
Apr 04, 2022 07:00 am ET
Colombian Government Provides Final Commercial Guidelines Related to the Export of Dried Flower
Builds on the passing of Regulation 227 in February, which implemented legal provisions to enable dried flower export and access to additional opportunities for CBD-based products.PharmaCielo expects to begin exporting dried flower in the second quarter of 2022, with volumes growing through the remainder of the year.TORONTO and RIONEGRO, Colombia, April 4, 2022 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdi
Mar 04, 2022 03:03 pm ET
PharmaCielo Provides Update on Non-Brokered Private Placement of Debenture Units
TORONTO and RIONEGRO, Colombia, March 4, 2022 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), today provided investors with an update on its non-brokered private placement of debenture units.
Feb 22, 2022 07:19 am ET
/R E P E A T -- Colombian Government Passes Regulation to Enable Dried Flower Export and Expand Industrial Applications for CBD-Based Products/
PharmaCielo expects to begin exporting dried flower in the first half of 2022, with volumes growing through the remainder of the year.The Company's upstream and downstream scale and quality uniquely position it to be a formidable competitor with psychoactive flower currently being imported into the EU and other markets from Canada and other producing countries.The new regulation also creates greater legal clarity, provides quotas for a new low-THC extract category and offers producers new business opportunities.TORONTO, Canada and RIONEGRO, Colombia, Feb. 20, 2022 /CNW/ - PharmaCielo Ltd. ("
Feb 14, 2022 06:45 am ET
PharmaCielo Signs Sales Agreement with Greenstein to Supply THC Final Products that will be Commercialized through NOWEDA, a Pharmaceutical Wholesaler to all Pharmacies Across Germany
The Company will start supplying the German market with three THC-dominant products, with commercial shipments expected to begin in late 2022. This is PharmaCielo's first sales agreement related to THC products. Represents a significant milestone related to management's re-focusing of PharmaCielo's product strategy toward THC-dominant products. TORONTO and RIONEGRO, Colombia, Feb. 14, 2022 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo
Dec 31, 2021 04:00 pm ET
PharmaCielo Completes Initial Tranche of Non-Brokered Private Placement of Debenture Units
All amounts expressed in Canadian dollars unless otherwise noted
Dec 22, 2021 06:45 am ET
PharmaCielo Announces $15.0 Million Non-Brokered Private Placement of Debenture Units
All amounts expressed in Canadian dollars unless otherwise noted
Nov 29, 2021 06:45 am ET
PharmaCielo Announces Q3-2021 Financial Results
Received confirmation of Colombian GMP Certification for Phytotherapeutics manufactured with proprietary PharmaCielo extracts and cultivars. Currently working toward EU-GMP certification, expected to be achieved in the first half of 2022. Executing on opportunities to streamline the business – In the three months ended September 30, 2021, the Company reduced its Adjusted EBITDA loss from $7.2 million to $4.3 million. PharmaCielo's upstream and downstream scale and quality uniquely position the Company to be a dominant competitor with current suppliers of psychoactive flower to the EU and oth
Sep 14, 2021 07:30 am ET
PharmaCielo Receives Confirmation of Colombian Phytotherapeutics GMP Certification
PharmaCielo Ltd. (“PharmaCielo” or the “Company”) (TSXV: PCLO, OTCQX: PCLOF), the Canadian parent of Colombia’s premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., today announced that it has...
Sep 01, 2021 07:30 am ET
PharmaCielo Announces the Appointment of Cannabis Industry Veterans Bob DeGabrielle and Will Nicholas to the Company's Board
Mr. DeGabrielle was an early entrepreneur and executive in the U.S. cannabis industry; he founded and owns Los Sueños Farms LLC, the largest outdoor grow in North America, which he recently agreed to sell to Curaleaf, Inc. Mr. Nicholas is an experienced finance professional and an early investor in the global cannabis industry; he was one of the founding shareholders of Alternative Medical Enterprises LLC, which merged with Verano Holdings LLC in December 2020. TORONTO and RIONEGRO, Colombia, Sept. 1, 2021 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF)
Aug 20, 2021 07:30 am ET
PharmaCielo Announces Q2-2021 Financial Results and Appointment of Bill Petron as CEO
On track for Revenue growth in the back half of fiscal 2021, as recently signed sales agreements translate into higher volumes. Generated early revenue from more than ten countries in the quarter. Bill Petron, the Company's Chairman and a global operations and cannabis veteran, has been appointed Chief Executive Officer of PharmaCielo. Most recently, Mr. Petron co-founded Alternative Medical Enterprises LLC, and co-led the company through its December 2020 merger with Verano Holdings LLC.All figures are in Canadian dollars ($) unless otherwise specified
Aug 04, 2021 07:30 am ET
PharmaCielo Signs Sales Agreement and Makes Initial Commercial Sale to Pharmaceutical Player in Brazil
The Customer is focused on medicine development, manufacture and distribution, and is one of the first pharmaceutical players to be fully licensed by the Brazilian Health Regulatory Agency (ANVISA) to produce cannabis products in the country. Agreement covers two CBD-dominant formulations and two THC-dominant formulations. Represents continued traction in the Brazilian market following the Company's April 26th announcement that it had made initial shipments to one of Brazil's largest Phyto-Therapeutics companies as well as to a large Pharmaceutical company in the market. TORONTO and RIONEGR
Jul 26, 2021 06:30 am ET
PharmaCielo Welcomes Colombian Government's New Cannabis Decree
The updated set of regulations opens doors for new cannabis-derived product categories to be developed and sold domestically and for export Decree addresses and closes regulatory gaps; improves Colombian cannabis industry's competitiveness on a global scale Opens the path for the development and sale of additional THC product types, as well as the commercial export of dried flower. TORONTO and RIONEGRO, Colombia, July 26, 2021 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal
Jun 23, 2021 06:30 am ET
PharmaCielo to Participate in the Cantor Fitzgerald International Cannabis Forum
TORONTO and RIONEGRO, Colombia, June 23, 2021 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., today announced that Henning von Koss, Chief Executive Officer will participate in a discussion at the Cantor Fitzgerald International Cannabis Forum on June 28, 2021.
Jun 15, 2021 06:30 am ET
PharmaCielo Makes Initial Shipment to Canadian Life Sciences Company
Customer to use PharmaCielo's CBD Isolate for expanded research and development of an innovative sublingual product platform. TORONTO and RIONEGRO, Colombia, June 15, 2021 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., today announced that it has made an initial shipment of CBD Isolate (the "Product") to a Canadian life sciences company that specializes in developing and commercializing proprietary drug-delivery
Jun 10, 2021 01:51 pm ET
PharmaCielo Announces Election of Directors - Welcomes Bill Petron, a Global Operations and Cannabis Veteran, as Chairman of the Board
Most recently, Mr. Petron co-founded Alternative Medical Enterprises LLC, and co-led the company through its December 2020 merger with Verano Holdings LLC. TORONTO and RIONEGRO, Colombia, June 10, 2021 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., today announced that all of the nominees listed in the Management Information Circular dated May 11, 2021, were elected as directors of the Company, as a result of a
May 31, 2021 07:30 am ET
PharmaCielo Announces Financial Results for the First Quarter Ended March 31, 2021
Recurring orders during Q1 2021 supported 31% Revenue growth compared to Q1 2020. Strong first quarter growth in demand for PharmaCielo's products, demonstrated by increased volume and repeat sales of CBD isolate and more complex products such as Broad-Spectrum Distillate. Continued growth in interest from potential customers in initiating GMP/EU GMP compliance audits, which the Company sees as one indicator of future demand. Targeted efficiency initiatives and streamlined organizational model resulted in a 17% reduction in total SG&A1 expenses compared to Q1 2020. Ian D. Atacan to becom
May 31, 2021 07:30 am ET
PharmaCielo Appoints Experienced Cannabis Executive Ian D. Atacan as Chief Financial Officer
TORONTO, Canada and RIONEGRO, Colombia, May 31, 2021 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO), (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., today announced that experienced financial and cannabis executive Ian D. Atacan has been appointed Chief Financial Officer of the Company, effective June 7, 2021, to replace CFO Scott Laitinen, who is retiring, effective June 1, 2021.
May 13, 2021 07:30 am ET
PharmaCielo Announces Bill Petron, a Global Operations and Cannabis Veteran, to Stand for Election as a Nominee for Chairman of the Board
Mr. Petron has a diverse and successful background scaling global manufacturing, logistics and medical cannabis operations. Most recently, Mr. Petron co-founded Alternative Medical Enterprises LLC, and co-led the company through its December 2020 merger with Verano Holdings LLC. Current Chairman, Simon Langelier, has decided not to stand for re-election at the Company's Annual General and Special Meeting of Shareholders, to be held on June 10, 2021. TORONTO, and RIONEGRO, Colombia, May 13, 2021 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadi
May 05, 2021 07:00 am ET
PharmaCielo Provides Update on Global GMP Compliance Process
Continues to advance sales pipeline – potential customers in Germany, Poland and Australia have scheduled EU-GMP and GMP1 validation audits. Follows a recently completed GMP validation audit process by a large Brazilian Phyto-therapeutic customer in late April. TORONTO and RIONEGRO, Colombia, May 5, 2021 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., today announced that potential customers from Germany, Poland
May 03, 2021 06:30 am ET
PharmaCielo Announces Financial Results for the Fourth Quarter and Fiscal Year Ended December 31, 2020
FY 2020 Revenue of $2.7 million compared to $0.8 million in FY 2019. Achieved key milestones foundational to future commercial success: Completed one of the world's largest processing and extraction complexes1, introduced a broad cannabinoid product portfolio and began validation of GMP2 and EU-GMP2 standards with potential clients expanding access to pharmaceutical markets. Streamlined operations resulting in a considerable reduction in run-rate SG&A expenses. Adds experienced Global Head of Business Development and Sales to complement commercial organization and execute on business dev
Apr 26, 2021 07:30 am ET
PharmaCielo Makes Initial Shipments to two Brazilian Customers
Shipments to established Pharmaceutical and Phyto-Therapeutics companies will offer PharmaCielo and its APIs1 early integration into the supply chain. Shipments followed an audit by the Phyto-Therapeutics customer, that confirmed PharmaCielo's compliance with Brazilian GMP standards. TORONTO, and RIONEGRO, Colombia, April 26, 2021 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., today announced that it has complet
Apr 07, 2021 09:01 am ET
PharmaCielo Announces Closing of Overnight Marketed Equity Offering for Gross Proceeds of $13.5 Million
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
Mar 31, 2021 08:00 am ET
PharmaCielo Provides Corporate Update
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
Mar 25, 2021 04:11 pm ET
IIROC Trading Resumption - PCLO.WT
VANCOUVER, BC, March 25, 2021 /CNW/ - Trading resumes in:
Mar 12, 2021 06:45 am ET
Mexico Votes to Advance Recreational Cannabis Legalization - PharmaCielo Mexico Positioned to Become a Preferred Supplier
On March 10th, Mexico's Chamber of Deputies voted 316 to 129 to advance a bill that would legalize recreational cannabis use in the country. With a population of more than 125 million people1 and a potential market value of USD$3.2 billion2, Mexico is set to become the largest legal cannabis market in the world. PharmaCielo Mexico is well-positioned to be a supplier of choice; PharmaCielo on track to receive Mexican GMP3 certification during Q2'21. TORONTO and RIONEGRO, Colombia, March 12, 2021 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadi
Mar 04, 2021 10:57 am ET
IIROC Trading Resumption - PCLO
VANCOUVER, BC, March 4, 2021 /CNW/ - Trading resumes in:
Mar 04, 2021 10:44 am ET
PharmaCielo Ltd. Announces Upsize and Pricing of Overnight Marketed Equity Offering
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
Mar 03, 2021 03:49 pm ET
IIROC Trading Halt - PCLO
VANCOUVER, BC, March 3, 2021 /CNW/ - The following issues have been halted by IIROC:
Mar 03, 2021 03:22 pm ET
PharmaCielo Ltd. Announces Overnight Marketed Equity Financing
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./
Feb 18, 2021 07:00 am ET
PharmaCielo Delivers First Commercial Shipment of THC-Free Broad-Spectrum Distillate
Shipped to existing Customer with operations in the U.K. and the E.U. THC-free broad-spectrum distillate from a single cultivar is a superior core formulation for nutraceutical and cosmetic formulations PharmaCielo is among the few global producers that deliver broad-spectrum formulations produced from specially selected, developed and standardized cultivars to B2B customers at consistently high quality and commercial scale. TORONTO and RIONEGRO, Colombia, Feb. 18, 2021 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's p
Feb 02, 2021 07:00 am ET
PharmaCielo Provides Update on GMP Compliance Process
Colombian and Mexican GMP certifications expected during Q1'21 and Q2'21, respectively The Company confirms that its recently completed Processing and Extraction Center at its Rionegro facility, Colombia's largest scale processing centre, will be producing extracts in compliance with EU-GMP guidelines by the end of February. TORONTO and RIONEGRO, Colombia, Feb. 2, 2021 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.
Dec 18, 2020 04:21 pm ET
PharmaCielo Announces Appointment of Caroline Lenardon for Expansion of Retail Investor Relations Capacity
TORONTO, Dec. 18, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S. today announced that the company has expanded investor relations support capacity with the appointment of Caroline Lenardon to provide investor relations services to the Company with a focus on retail investment. The institutional investor market will continue to be supported by the existing contractor.
Dec 11, 2020 07:30 am ET
PharmaCielo Enters Strategic Alliance to Provide Pre-Tested and Insured Product to Customers in the U.S. Market
Alliance with AssuredTrans Inc. will enable PharmaCielo to provide up-front independent laboratory analysis and insurance of its recently expanded product portfolio to potential customers in the U.S., beginning in 2021 Former congressman notes alliance enables U.S. customers to have confidence in the purity and quality of PharmaCielo's products TORONTO, ON and CORAL SPRINGS, Fla., Dec. 11, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCi
Dec 07, 2020 07:30 am ET
PharmaCielo Receives Approximately CDN$3.0 Million in Non-Dilutive Funding from Colombian State-Owned Banco Agrario
Loan of COP$8.5 billion (approximately CDN$3.0 million1) has an 84-month term, 10.14% coupon and revolving component with no equity dilution This loan together with the proceeds of the recent CDN$10mm equity financing put the company in a well-capitalized position to execute on its growing sales pipeline. TORONTO and RIONEGRO, Colombia, Dec. 7, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("PharmaCielo Col
Dec 03, 2020 07:30 am ET
PharmaCielo Welcomes Landmark United Nations Decision to Remove Cannabis from Narcotic Drugs List
TORONTO, Dec. 3, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF) the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("PharmaCielo Holdings"), commends the United Nations Commission on Narcotic Drugs (CND) for its historic decision to remove cannabis from the global narcotic drugs list, also known as the Single Convention on Narcotic Drugs (Schedule IV). PharmaCielo maintains operations and joint ventures in Canada, Colombia, Mexico and Italy – each nation of w
Dec 02, 2020 05:00 am ET
PharmaCielo Announces Grant of Stock Options
TORONTO and RIONEGRO, Colombia, Dec. 2, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S. ("PharmaCielo Holdings"), today announced that the board of directors of the Company approved the grant of 200,000 stock options ("Stock Options"), each Stock Option being exercisable to acquire one common share of the Company (a "Common Share") at a price of $1.11 per Common Share for a period of 10 years from the date of issuance, to Henning
Nov 30, 2020 06:30 am ET
PharmaCielo Announces Financial Results for the Third Quarter Ended September 30, 2020
Effective December 1, Henning von Koss has been named CEO of PharmaCielo, replacing departing CEO David Attard. Successful achievement of Q3 operational milestones: Processing and Extraction Centre ("PEC") construction completed – one of largest current extraction footprints1 globally; expanded product portfolio launched. Plan to initiate GMP2 certification process during Q4 with expected completion during Q1-2021. Refreshed go-to-market strategy initiated during Q3 driving early traction in Q4 – recently entered the U.K. market.All figures are in Canadian dollars ($) unless otherwise specif
Nov 30, 2020 06:30 am ET
PharmaCielo Ltd. Announces New Leadership
David Attard and Board of Directors reach mutual agreement under which David will step down as Chief Executive Officer and PharmaCielo board member, effective December 1st, 2020. Henning von Koss, currently President and a member of PharmaCielo's Board of Directors, formerly with Bayer and 30-year career as senior executive with operations focus, has been appointed CEO and will continue as a director. TORONTO, Nov. 30, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF) announced that David Attard will step down as CEO and PharmaCielo board member effe
Nov 25, 2020 07:30 am ET
PharmaCielo Achieves Good Agricultural and Collection Practices (GACP) Designation
Designation brings PharmaCielo a step closer to EU-GMP compliance; supports continued expansion of medicinal-grade extract exports GACP certification is based on WHO guidelines for quality assurance and control of herbal medicines TORONTO and RIONEGRO, Colombia, Nov. 25, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian-headquartered medicinal cannabis company with cultivation and extraction operations in Colombia, announced that its subsidiary, PharmaCielo Colombia Holdings S.A.S., has received the Good Agricultural and Collection Prac
Nov 23, 2020 07:30 am ET
PharmaCielo Announces Closing of $10M Private Placement
TORONTO, Nov. 23, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF) is pleased to announce the closing of its previously announced private placement of units ("Units") of the Company for gross proceeds of $10.0 million.
Nov 19, 2020 07:30 am ET
PharmaCielo Mexico Salutes Mexican Senate for Advancing Cannabis Legalization
TORONTO and MEXICO CITY, Nov. 19, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF) and MINO Labs S.A. de C.V. ("MINO Labs"), the founders of PharmaCielo S.A. de C.V. ("PharmaCielo Mexico"), congratulate Mexican Senate members for advancing the much-needed cannabis legislation and subsequent reform by voting to move forward the legalization bill, which includes provision for import of medicinal extracts and products.
Nov 18, 2020 07:30 am ET
PharmaCielo Enters U.K. Market with 500kg Initial Shipment to Established Manufacturer and Distributor - Reaches 2021 Agreement
Including Initial Shipment, PharmaCielo will deliver total 1,000 kg of product to Customer – with revenue and cash flow reflected in 2020; interim 2021 sales agreement reached for continued Q1 volume and revenue. Relationship adds U.K. and additional E.U. exposure to PharmaCielo's current commercial relationships in the U.S., Germany, Switzerland and broader E.U. Currently submitting for Novel Foods Certification to support volume growth of CBD Isolate and Broad Spectrum as consumable ingredient in the U.K. and E.U. markets. TORONTO and RIONEGRO, Colombia, Nov. 18, 2020 /CNW/ - PharmaCielo
Nov 16, 2020 06:30 am ET
PharmaCielo to Hold Conference Call to Review Third Quarter 2020 Financial Results
TORONTO and RIONEGRO, Colombia, Nov. 12, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., announced today that it will host a conference call on Monday, November 30th, 2020, at 8:00 a.m. ET to discuss its third quarter financial results and provide investors with key business highlights. The call will be chaired by David Attard, CEO and Scott Laitinen, CFO.
Nov 13, 2020 07:00 am ET
PharmaCielo to Participate in 2020 Cowen Boston Cannabis Conference
TORONTO, Nov. 13, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., announced today that it will be participating in Cowen's 2020 Boston Cannabis Conference, to be held virtually between November 30 and December 2, 2020.
Nov 05, 2020 06:30 am ET
PharmaCielo Begins Harvest of High-THC Cultivars for Extract Export
First harvest cycle of high-THC cultivars expected to yield more than 10 tonnes of dry flower for extract processing Extracts from six psychoactive cultivars part of Company's expanded product portfolio announced in mid-September Company holds Government approval for commercial export of high-THC extracts TORONTO and RIONEGRO, Colombia, Nov. 5, 2020 /CNW/ - PharmaCielo Ltd. (or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., is pleased to announce the fi
Nov 03, 2020 06:30 am ET
PharmaCielo Announces Upsizing of Private Placement Offering
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
Nov 02, 2020 04:27 pm ET
PharmaCielo Ltd. Expands Board Depth and Expertise with Appointment of Marc Lustig as Lead Director and Strengthens Capital Position with Private Placement Offering
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
Oct 23, 2020 08:00 am ET
PharmaCielo to Participate in Cantor Fitzgerald Latin America Cannabis Seminar
TORONTO, Oct. 23, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., announced today that it will be participating in Cantor Fitzgerald's Latin America Cannabis Seminar, to be held virtually on Wednesday October 28, 2020.
Oct 06, 2020 09:47 am ET
Horizons ETFs Rebalances Marijuana-Focused Index ETF Suite
TORONTO, Oct. 6, 2020 /CNW/ - Horizons ETFs Management (Canada) Inc. ("Horizons ETFs") has completed the quarterly rebalance of the constituent holdings of the Horizons Marijuana Life Sciences Index ETF ("HMMJ":TSX) and the Horizons US Marijuana Index ETF ("HMUS":NEO).
Sep 22, 2020 08:20 am ET
PharmaCielo Declared 'Project of National Strategic Interest' by Government of Colombia
TORONTO and RIONEGRO, Colombia, Sept. 22, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., is very pleased to announce that the Colombian Intersectoral Commission for Strategic Projects (Comisión Intersectorial de Proyectos Estratégicos – CIPE) led by the Minister for Medical Cannabis, Ernesto Lucena Barrero, has identified PharmaCielo as a 'Project of National Strategic Interest' (Proyectos de Interés Naciona
Sep 21, 2020 08:00 am ET
PharmaCielo Expands Portfolio of Cannabis Extracts to Meet Global B2B Medical-Grade Market Demand
New offerings allow PharmaCielo to respond to market demand with expanded product range Extracts derived from proprietary cultivars and produced internally at 30,000+ sq. ft. processing and extraction facility Independent analytical verification of unique medicinal profile and high quality Current inventories support immediate new product sales TORONTO and RIONEGRO, Colombia, Sept. 21, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo
Aug 31, 2020 07:30 am ET
PharmaCielo Announces Financial Results for the Second Quarter Ended June 30, 2020 and Provides Operational Update
Revenue continues to accelerate. The Company generated $1.2 million in revenue during Q2-2020, reaching $1.7 Million YTD 2020 compared to $786,901 in its full 2019 fiscal year. Recent increase in active cultivation footprint readies PharmaCielo to process and deliver more extracted product during the second half of 2020 and into 2021. Production from the Company's Processing and Extraction Centre will begin accelerating during Q3-2020. The Company intends to initiate the GMP certification process during Q4-2020, which will enable it to both expand its customer base and enter new markets in 2
Aug 18, 2020 07:30 am ET
PharmaCielo to Hold Conference Call to Review Second Quarter 2020 Financial Results
TORONTO and RIONEGRO, Colombia, Aug. 18, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., announced today that it will host a conference call on Monday, August 31st, 2020, at 8:30 a.m. ET to discuss its second quarter financial results and provide investors with key business highlights. The call will be chaired by David Attard, CEO, Henning Von Koss, President, David Gordon, CCO and Scott Laitinen, CFO.
Aug 13, 2020 07:30 am ET
PharmaCielo Increases Cannabis Cultivation Through External Contractor to Meet Market Demand for Medicinal Extracts
Additional area under active cultivation expands PharmaCielo's immediate footprint by 32 percent to 1.6 million square feet with further expansion pending grower license approval Company activates first external cultivation contract with local grower Increased volumes contribute to expanded 360 tonne biomass processing capacity of the Company's new Processing and Extraction Centre TORONTO and RIONEGRO, Colombia, Aug. 13, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-
Aug 07, 2020 12:29 pm ET
PharmaCielo Announces Results of AGM
TORONTO, Aug. 7, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., is pleased to announce the results of the Company's annual general and special meeting (the "AGM") held virtually on August 6, 2020.
Jul 08, 2020 08:30 am ET
PharmaCielo Receives Colombian Government Authorization for 10 Tonnes of High-THC Cultivation and Extract Production for Export
Enables PharmaCielo to produce and deliver psychoactive extracts as part of the three-year extracts agreement the Company announced in January of this year, intended for the German market Enhances product development flexibility and will accelerate PharmaCielo's strategic priority to expand beyond CBD oils and isolates to meet market demand TORONTO and RIONEGRO, Colombia, July 8, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colom
Jul 03, 2020 10:57 am ET
PharmaCielo Ltd. Closes $4.6 Million Bought Deal Offering
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FORDISSEMINATION IN THE UNITED STATES./
Jun 29, 2020 08:34 pm ET
PharmaCielo Ltd. Files Final Prospectus for $4 Million Bought Deal Offering
TORONTO, June 29, 2020 /CNW/ - PharmaCielo Ltd. (the "Company" or "PharmaCielo") (TSXV:PCLO) (OTCQX: PCLOF) is pleased to announce that it has filed a (final) short form prospectus with the securities regulatory authorities in British Columbia, Alberta, Ontario and Quebec in connection with its previously announced $4 million "bought deal" offering of common shares (the "Offering"), co-led by Cormark Securities Inc. and Stifel GMP. The Offering is expected to close on or about July 3, 2020 and is subject to regulatory approval including that of the TSX Venture Exchange. The net proceeds of t
Jun 10, 2020 07:51 am ET
PharmaCielo Ltd. Announces $4,000,000 Bought Deal Public Offering
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
Jun 01, 2020 08:00 am ET
PharmaCielo Announces Financial Results for the First Quarter Ended March 31, 2020 and Provides Operational Update
PharmaCielo generated $514,409 in revenue during Q1-2020, compared to revenue of $786,901 in its full 2019 fiscal year. Pro forma cash and cash equivalents of $12.7 million1. Processing equipment is now on-site in Rionegro; the Company expects to be in a position to begin accepting broad spectrum commercial pre-orders by the end of Q2. All figures are in Canadian dollars ($) unless otherwise specified
May 15, 2020 05:49 pm ET
PharmaCielo Ltd. Obtains Final Receipt for Short Form Prospectus
TORONTO, May 15, 2020 /CNW/ - PharmaCielo Ltd. (the "Company" or "PharmaCielo") (TSXV:PCLO) (OTCQX: PCLOF) is pleased to announce today that it has obtained a receipt for the Company's (final) short form prospectus dated May 15, 2020 (the "Prospectus"), filed with the securities regulatory authorities in the provinces of British Columbia, Ontario, and Québec. The Prospectus qualifies the distribution of 12,578,002 common shares (the "Special Warrant Shares") of the Company issuable upon the exercise or deemed exercise of 12,578,002 previously issued special warrants (the "Special Warrants"),
May 12, 2020 07:30 am ET
PharmaCielo Welcomes Dr. Claudia Jiménez to Board of Directors
TORONTO, May 12, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO, OTCQX: PCLOF) is pleased to welcome Dr. Claudia Jiménez (Ph.D.) to its board of directors. As a board member, Dr. Jiménez will also serve on the Company's Audit, Nominating and Corporate Governance committees. Dr. Jiménez's appointment is effective June 1, 2020.
May 04, 2020 12:02 pm ET
PharmaCielo Adds Experienced Senior Leader to Executive Team
Henning von Koss – a proven 30-year veteran of the global pharmaceutical, chemical and healthcare industries – named President to focus on scaling international operations
Apr 30, 2020 05:00 am ET
PharmaCielo Announces Financial Results for the Fourth Quarter and Fiscal Year Ended December 31, 2019
PharmaCielo generated a record $657,000 in revenue during Q4. Generated revenue of $786,901 in fiscal 2019. $13.7 million in cash and cash equivalents at December 31, 2019; Subsequent to the end of the quarter, the Company closed a private placement financing for gross proceeds of approximately $8 million.All figures are in Canadian dollars ($) unless otherwise specified
Apr 29, 2020 02:28 pm ET
PharmaCielo Provides Details for Fourth Quarter and Year-End 2019 Results Conference Call
TORONTO, April 29, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTCQX:PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., advised today that it will be holding its fourth quarter and fiscal 2019 financial results conference call on April 30, 2020 at 9:00 a.m. ET. While the Company's usual year-end audit process was delayed as a result of the ongoing COVID-19 pandemic, the Company will be filing its financial results tonight, April 29, 2020, consistent with the regul
Apr 15, 2020 07:49 pm ET
PharmaCielo Ltd. Announces Closing of Previously Announced $8 Million Private Placement Financing
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./
Apr 06, 2020 06:59 pm ET
PharmaCielo Ltd. Prices $8 Million Offering; Closing Scheduled for April 14
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./
Apr 01, 2020 05:41 pm ET
PharmaCielo Ltd. Announces Best Efforts Private Placement Offering
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
Mar 23, 2020 07:15 am ET
PharmaCielo Independent Investigation Concludes Short-seller Report Contains Accusations and Claims based on Faulty Interpretation of Events and Information
Company invites shareholders to review its full response, the Independent Review findings and supporting evidence at https://bit.ly/2wy4fNs TORONTO, March 23, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO, OTCQX: PCLOF), has issued the Company's detailed response to a short seller report that contains incorrect analysis of a broad range of events and information on the Company's operations, land and property acquisitions, marketing and distribution contracts, and claims about the founders and directors, among others. The Company referenced the misleading short
Mar 03, 2020 05:30 am ET
PharmaCielo Issues Statement Regarding Misleading Short Seller Report
TORONTO, March 3, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO, OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., announced that it is aware that a short seller report targeting PharmaCielo has been promoted this week. The Company believes that this report represents a malicious attempt to manipulate PharmaCielo's common shares by spreading false, distorted and misleading statements about the Company.
Jan 27, 2020 07:30 am ET
XPhyto Therapeutics Announces Strategic Supply, Import and Distribution Agreement for the German Cannabis Market
Vancouver, British Columbia--(Newsfile Corp. - January 27, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) ("XPhyto" or the "Company") is pleased to announce that the Company has signed a three year definitive supply, import and distribution agreement (the "Agreement") with PharmaCielo Ltd. ("PharmaCielo"), one of the largest, highest quality, and lowest cost cannabis cultivators in the world.
Jan 27, 2020 06:30 am ET
PharmaCielo Announces 30,000 Kg Cannabis Extract Agreement for German Market
PharmaCielo will sell a broad range of extracts – including both CBD- and THC-dominant profiles – to XPhyto Therapeutics Corp., for German market distribution Three-year agreement signed, covering a minimum delivery target of 30,000 kg, beginning mid-2020 GAP and ISO 9001:2015 Certifications Provide Key Quality Confirmation to Customer TORONTO, Jan. 27, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO; OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., announce
Jan 24, 2020 06:30 am ET
PharmaCielo Signs Pan-European Distribution Agreement for CBD Isolate and Broad-Spectrum CBD Oil
Company signs a three-year performance-based agreement with CBD Export Global Distribution channel covers the entire EU-zone as well as Switzerland and Lichtenstein Shipments to commence in 2020 with increasing volumes during duration of Agreement TORONTO and RIONEGRO, Colombia, Jan. 24, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO, OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., announces it has signed a three-year pan-European distribution agreement (
Jan 22, 2020 06:30 am ET
PharmaCielo Added to XCAN - the Newly Created S&P/TSX Cannabis Index
TORONTO, Jan. 22, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO, OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., is pleased to announce that it has been included in the newly created S&P/TSX Cannabis Index (XCAN). The XCAN is composed of a select group of issuers traded on the TSX and TSX Venture Exchanges, each of which has been vetted by the TSX Market Intelligence Group.
Jan 20, 2020 09:30 am ET
PharmaCielo Becomes First Cultivator Awarded Good Agricultural Practices (GAP) Global Certification for Colombian Medicinal-Cannabis Operations
PharmaCielo is the first cannabis cultivator evaluated by Swiss founded SGS to meet international certification standards Good Agricultural Practices (GAP) certification testament to safe and sustainable cultivation practices; supportive of Good Manufacturing Practices (GMP) designation continuum and international market sales GAP skill set evidenced by cultivar registration of additional 10 unique strains; total of 30 unique and proprietary strains now registered for commercial use TORONTO and RIONEGRO, Colombia, Jan. 20, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV
Jan 17, 2020 06:00 am ET
PharmaCielo Receives Acceptance from TSX Venture Exchange of Supply Agreement for Export of 2018 Farm Bill Compliant CBD Isolate to United States
TORONTO, Jan. 17, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO, OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., announced that further to its September 25, 2019 press release relating to a supply agreement (the "Supply Agreement") it has received TSX Venture Exchange ( "TSXV") approval of the export from Colombia of medicinal grade CBD isolate that is compliant with the 2018 Farm Bill to a distributor in the United States who had placed an order for up to
Dec 14, 2019 09:38 am ET
PharmaCielo Awarded Game-Changer Award by MJDaily
PharmaCielo receives game-changer award for the Latin America Region Company celebrated for pioneering role in building Colombia's medical cannabis industry TORONTO and RIONEGRO, Colombia, Dec. 14, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO, OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., has been recognized with the prestigious MJ Biz Daily Game-Changer Award for the Latin America Region. The inaugural award was presented to the Company at a special g
Dec 05, 2019 06:00 am ET
PharmaCielo Announces Receipt of CAD$3.9 Million Secured Loan Repayment
TORONTO, Dec. 5, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., announced that Creso Pharma Limited ("Creso") (ASX:CPH) has repaid in full, all principal and interest owing to the Company in the amount of approximately CAD$3.9 million under the secured bridge loan by PharmaCielo to Creso that was made pursuant to an amendment to Creso's existing loan deed, originally entered into with an arm's length party to Creso
Dec 02, 2019 06:00 am ET
PharmaCielo Graduates to OTCQX® Best Market and Secures DTC Eligibility
Qualification to trade on the OTCQX® Best Market is expected to offer greater visibility for the Company's shares and improved liquidity New U.S. ticker symbol (PCLOF) aligned with Company's Canadian TSX Venture Exchange ("TSXV") ticker PCLO DTC eligibility helps provide investors easy access and liquidity in all jurisdictions TORONTO, Dec. 2, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., is pleased to annou
Nov 25, 2019 09:50 am ET
PharmaCielo to Hold Conference Call to Review Third Quarter 2019 Financial Results
TORONTO, Nov. 25, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., announces today that it will host a conference call on Monday, November 25th, 2019, at 5:00 p.m. ET to discuss its third quarter financial results and provide investors with key business highlights. The call will be chaired by David Attard, CEO; David Gordon, CCO and Scott Laitinen, CFO.
Nov 25, 2019 06:00 am ET
PharmaCielo Announces Financial Results for the Three and Nine Months Ended September 30, 2019
"All-in" cost to produce dried cannabis of $0.04i per gram in Q3 – 20% better than targeted. Net loss significantly reduced to $3.8 million compared to $10.7 million in Q2-2019. Well capitalized with cash and short-term investments of $20.7 million as of September 30, 2019. Initiating commercial sales – Completed sales negotiation in Q3-2019 to ship a minimum of $3 million worth of bulk CBD isolate to a distributor in the U.S. during Q4-2019. Nearing completion of extraction and processing center ("RTC"), which will expand the Company's extraction capacity to 265 tonnes of dried flower per y
Nov 08, 2019 07:39 pm ET
PharmaCielo Announces RSU Grant
TORONTO, Nov. 8, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTC:PHCEF) today announced that on November 5, 2019 (the "Grant Date") the board of directors approved and granted 25,000 restricted share units ("RSUs") to Carlos Manuel Uribe, a director of the Company, which all vest on the Grant Date. Each RSU entitles the holder to receive one common share in the capital of the Company (each a "Common Share") upon vesting.
Nov 06, 2019 08:14 am ET
IIROC Trading Resumption - PCLO
VANCOUVER, Nov. 6, 2019 /CNW/ - Trading resumes in:
Nov 05, 2019 04:07 pm ET
PharmaCielo Announces Termination of Scheme Implementation Agreement with Creso Pharma
TORONTO, Nov. 5, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTC:PHCEF) announces that earlier today it was advised by Creso Pharma Limited ("Creso Pharma") that due to BDO Corporate Finance (WA) Pty Ltd. changing its independent expert report to conclude that the PharmaCielo Share Scheme is neither fair nor reasonable and is not in the best interests of shareholders of Creso Pharma, it is impossible for the Board of Directors of Creso Pharma to support the Share and Option Schemes (the "Schemes") in their current form. As a result of the Creso Pharma Board of
Nov 04, 2019 12:51 pm ET
PharmaCielo Trading Halted Pending Update from Creso Pharma
TORONTO, Nov. 4, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO), today announced that trading in its common shares was halted today, pending an update from Creso Pharma Limited ("Creso Pharma") in respect of PharmaCielo's proposed acquisition of the company, which was originally announced on June 6, 2019.
Nov 04, 2019 08:30 am ET
IIROC Trading Halt - PCLO
VANCOUVER, Nov. 4, 2019 /CNW/ - The following issues have been halted by IIROC:
Nov 01, 2019 02:51 pm ET
IIROC Trading Resumption - PCLO
VANCOUVER, Nov. 1, 2019 /CNW/ - Trading resumes in:
Nov 01, 2019 02:41 pm ET
PharmaCielo Provides Update on Proposed Acquisition of Creso Pharma
TORONTO, Nov. 1, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO), today announced that in respect of its proposed acquisition of Creso Pharma Limited ("Creso Pharma") originally announced on June 6, 2019, and prior to the opening of the markets this morning, the Company was advised that Creso Pharma had received a supplementary independent expert report from BDO Corporate Finance (WA) Pty Ltd. updating its September 26, 2019 report, to now conclude that the Share Scheme of Arrangement (the "Share Scheme") under which PharmaCielo has proposed to acquire all of the i
Nov 01, 2019 09:34 am ET
IIROC Trading Halt - PCLO
VANCOUVER, Nov. 1, 2019 /CNW/ - The following issues have been halted by IIROC:
Oct 02, 2019 09:57 am ET
PharmaCielo Announces Creso Pharma's Receipt of Australian Court Approval to Convene Meeting of Shareholders
PharmaCielo's acquisition of Creso Pharma will establish a global medicinal cannabis company, positioned to rapidly develop new markets and grow sales in the expanded footprint served by the combined company.
Sep 27, 2019 12:12 pm ET
Horizons ETFs Rebalances Marijuana-Focused Index ETF Suite
Horizons ETFs maintains the world's largest suite of cannabis ETFs
Sep 25, 2019 07:00 am ET
PharmaCielo Enters the U.S. with $3 Million Q4 Sales Agreement and Completes Introductory Shipments to Multi-state Distributor General Extract LLC
2019 market introduction revenues projected at minimum $3 million CDN Agreement covers sales and distribution of medicinal CBD isolate in multiple US states commencing in 2019 with allowance for renewal and volume expansion in 2020 Introductory shipments, meeting CBD isolate requirements of 2018 Farm Bill, successfully completed Congressman Dana Rohrabacher, advisor to the Company, celebrates contribution to American medicinal community TORONTO, Sept. 25, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTC:PHCEF), the Canadian parent of Colombia's premier cultivat
Aug 27, 2019 07:00 am ET
PharmaCielo Announces Financial Results for the Second Quarter 2019
Well capitalized with a cash and short-term investments of $33.2 million as of June 30, 2019 Subsequent to quarter completed first commercial export of CBD from Colombia to Europe Have cleared all regulatory hurdles to begin exporting CBD isolate to multiple global markets Construction of Colombian processing facility nearing completion, capable of processing 265 tonnes of dried flower per yearAll figures are in Canadian dollars ($) unless otherwise specified
Aug 19, 2019 08:00 am ET
PharmaCielo's Very First Commercial CBD Export from Colombia Lands in Europe
Commercial shipment delivers CBD isolate to Switzerland-based Creso Pharma Company executed overseas commercial delivery weeks after securing the first commercial exporting permit from Colombian government announced July 25 Delivery demonstrates potential synergies between the two companies TORONTO and CHAM, Switzerland, Aug. 19, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTC:PHCEF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., confirmed today it successfully complete
Aug 13, 2019 08:00 am ET
PharmaCielo Expands Further Into Latin America With Sales Agreement to Supply CBD Extracts, Oils and Veterinary Products to Laboratorios Adler
CBD extracts and oils to be used in Adler's portfolio of veterinary products for pain and cancer treatment in large and domestic animals Agreement also includes supply of Creso Pharma's anibidiol® products This is PharmaCielo's first foray into the growing veterinary CBD market Agreement covers sales and distribution in Uruguay, Paraguay, Bolivia and Southern Brazil TORONTO and MONTEVIDEO, Uruguay, Aug. 13, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTC:PHCEF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil,
Aug 08, 2019 08:00 am ET
PharmaCielo Joins Canadian Market Cannabis Tracking and Verification Initiative
PharmaCielo is the first non-Canadian medical cannabis producer to join the Canadian Pilot Program TruTrace's technology offers full transparency and traceability of medical cannabis from the plant's cultivar DNA through to the final product – ensuring quality, standardization and enhanced product safety TORONTO and RIONEGRO, Colombia, Aug. 8, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTC:PHCEF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., today announced it has joi
Aug 02, 2019 08:00 am ET
PharmaCielo Colombia Holdings S.A.S. Appoints New and Diversified Board of Directors
New board consists of diversified experts with domestic and international business, academia, agriculture, trade and healthcare expertise Half of new board members are businesswomen, reflecting the overall balance of Company's workforce and commitment to inclusivity Board's mandate is focused on the Company's domestic growth and regulatory relations, aligned to support the international operations of parent company PharmaCielo Ltd. RIONEGRO, Colombia, Aug. 2, 2019 /CNW/ - The executive management team of PharmaCielo Ltd. (TSXV:PCLO, OTC:PHCEF) is pleased to announce the appointment of a new
Aug 01, 2019 08:00 am ET
PharmaCielo Achieves Twelvefold Increase in Dried Cannabis Processing Capacity to Meet Global Demand for Medicinal Oil Extracts
Investment of CDN$4 million expands Colombian processing capabilities twelvefold through addition of high-volume extraction equipment and proprietary techniques Annual extraction capacity increased to 265 tonnes, as Company has begun processing inventory of 18 tonnes of dried flower currently in storage Increased production of oil extracts will support international supply channels and product manufacturing following Creso Pharma acquisition closure PharmaCielo was recently granted approval for commercial export of non-psychoactive (CBD) isolate from the Colombian Government TORONTO and RIO
Jul 26, 2019 08:10 am ET
PharmaCielo Completes Acquisition of Ubiquo Telemedicina
Ubiquo Telemedicina S.A.S. is a leading provider of telemedicine services in Colombia Acquisition will enable expanded access to medicinal cannabis expertise among the Colombian medical community TORONTO, July 26, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., today announced that it has completed the acquisition of all of the shares (the "Acquisition") of Ubiquo Telemedicina S.A.S. ("Ubiquo Telemedicina"), previously announce
Jul 25, 2019 08:10 am ET
PharmaCielo First to Receive Colombian Government Export Approval for Commercial Sale of CBD Isolate
Completion of commercial export permit process clears the way for PharmaCielo to initiate shipment of its medicinal-grade CBD extracts to wholesale distributors and product manufacturers CBD isolate to be exported holds a purity certificate of analysis (COA) of 99+% and meets all other strict quality control standard requirements TORONTO and RIONEGRO, Colombia, July 25, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTC:PHCEF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A
Jul 22, 2019 07:30 am ET
PharmaCielo Colombia Holdings S.A.S. Appoints Andres Felipe Botero as Chief Operations Officer
Mr. Botero brings nearly two decades of domestic and international operational experience with industry giant Philip Morris International, most recently as Director of Operations for the Andean Cluster The appointment will help drive the growth of the Company's production capacity as it readies to feed global supply channels RIONEGRO, Colombia, July 22, 2019 /CNW/ - PharmaCielo Colombia Holdings S.A.S. ("PharmaCielo Colombia" or the "Company"), the premier cultivator and producer of medicinal-grade cannabis oils and extracts in Colombia and subsidiary of Canadian firm PharmaCielo Ltd. (TSXV
Jul 18, 2019 07:30 am ET
Blueberries Medical Makes Significant Advances Towards Commercial Production & Provides Operational and Corporate Update
Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the “Company” or "Blueberries"), a leading Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to provide investors with the following update...
Jun 21, 2019 08:00 am ET
PharmaCielo Announces Trading on the OTC Market
TORONTO and RIONEGRO, Colombia, June 21, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO) (OTC:PHCEF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., is pleased to announce that it is trading on the OTC Markets under the symbol "PHCEF".
Jun 06, 2019 10:48 am ET
IIROC Trading Resumption - PCLO
VANCOUVER, June 6, 2019 /CNW/ - Trading resumes in:
Jun 06, 2019 10:30 am ET
PharmaCielo to Acquire International Cannabis Company Creso Pharma for A$122 Million
Acquisition will add extensive on-shelf product portfolio available in multiple regions Expands PharmaCielo's global sales reach and market presence in Canada, Switzerland, Europe, Australia, New Zealand, Israel, and Brazil TORONTO, June 6, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., today announced that it has entered into a scheme implementation agreement (the "Implementation Agreement") pursuant to which PharmaCielo has
Jun 06, 2019 09:22 am ET
IIROC Trading Halt - PCLO
VANCOUVER, June 6, 2019 /CNW/ - The following issues have been halted by IIROC:
May 29, 2019 07:00 am ET
PharmaCielo Gears Up for U.S. Market Demand, Enlists Former Congressman and Medical Cannabis Advocate Dana Rohrabacher as a Special Advisor
Rohrabacher is a longstanding advocate for the legalization of medical cannabis Rohrabacher spearheaded historic U.S. legislation that protects medical cannabis patients TORONTO, May 29, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., announced today that it has enlisted former U.S. congressman and long-time medical cannabis advocate Dana Rohrabacher as a special advisor to the Company.
May 27, 2019 07:00 am ET
PharmaCielo Announces its Financial Results for the First Quarter 2019
Well capitalized with a cash and cash equivalents balance of $40.8 million as of March 31, 2019 Working towards first commercial sales in the 2nd half of 2019 Area under cultivation has grown to ~12 hectares from ~10 hectares at the end of 2018, a 20% increase in area under cultivation Construction of Colombian processing facility progressing toward production in late Q2/early Q3 Currently in active negotiations in multiple markets in South America and the EUAll figures are in CDN dollars unless otherwise specified
May 24, 2019 07:00 am ET
PharmaCielo Announces Results of AGM
TORONTO and RIONEGRO, Colombia, May 24, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., is pleased to announce the results of the Company's annual general and special meeting (the "AGM") held on May 23, 2019, in Toronto, Ontario.
Apr 18, 2019 07:50 am ET
PharmaCielo Announces its Financial Results for the Fourth Quarter and Fiscal Year 2018
PharmaCielo expects to begin commercial sales in 2019. Oil processing facility is on track for commercial operation and GMP certification during Q3-2019, enabling large-scale production and sale of refined cannabis oil. Currently, 10 hectares are under active cultivation, expanding to 20 hectares (~2.15 million square feet) by year-end 2019, backed by 20 proprietary registered strains and 186 strains in the Company's germplasm bank. PharmaCielo's common shares began trading on the TSX Venture Exchange ("TSXV" or "TSX Venture") under the ticker PCLO on January 18, 2019. Well capitalized with
Apr 09, 2019 07:00 am ET
PharmaCielo Appoints New and Extended Medical and Scientific Advisory Board
International panel of renowned physicians, researchers, veterinarians, engineers and academics Advisory Board to guide PharmaCielo's research and development of special cannabinoids-based formulations and derived products with therapeutic properties TORONTO and RIONEGRO, Colombia, April 9, 2019 /CNW/ - David Attard, Chief Executive Officer of PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., is pleased to announce the appointment of the Comp
Mar 29, 2019 08:00 am ET
PharmaCielo Doubles Its Portfolio of Proprietary Cannabis Strains Approved for Colombia's Cultivar Registration
Adds 10 new THC-dominant strains to previously approved group, including unique 1:1 ratio strain Company holds the largest and most diversified portfolio of cultivar-registered strains in Colombia PharmaCielo has 10 additional strain applications awaiting approval TORONTO and RIONEGRO, COLOMBIA, March 29, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., announced today that its Colombian subsidiary has received from the national
Mar 19, 2019 08:00 am ET
PharmaCielo Receives ISO 9001 Quality Assurance Certification for its Medicinal Cannabis Cultivation and Processing Operations in Colombia
PharmaCielo is the first and only Colombian cannabis company to receive the internationally recognized ISO 9001:2015 certification ISO 9001 certification affirms the company's commitment to producing the highest quality medicinal-grade cannabis oils and derived products TORONTO and RIONEGRO, Colombia, March 19, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., is pleased to announce the Company has received the ISO 9001:2015 certi
Mar 18, 2019 04:14 pm ET
Horizons ETFs Rebalances the Horizons Marijuana Life Sciences Index ETF
Quarterly rebalance includes a leading U.S.-based CBD producer
Feb 14, 2019 08:58 am ET
Top 3 Cannabis Stocks Higher on Colombian Growth Story
HOUSTON, TX / ACCESSWIRE / February 14, 2019 / Colombia is just beginning to transform itself into a multi-billion-dollar cannabis producer for the pharmaceutical industry. In time, growers estimate that the country could capture as much as a fifth of a global market that could be worth $40 billion a year, according to Reuters.
Feb 06, 2019 05:30 am ET
PharmaCielo Receives Approval for Cultivar Registration of 10 Proprietary Cannabis Strains
Colombia's only CBD-dominant strain meeting WHO purity standards among strains approved Establishes unique competitive advantage as sole licensed producer in Colombia of non-psychoactive strain WHO clarification regarding CBD expected to increase global medicinal demand PharmaCielo has additional 20 strain applications in process awaiting approval TORONTO and RIONEGRO, Colombia, Feb. 6, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.
Jan 28, 2019 05:30 am ET
PharmaCielo Establishes Joint Venture with Mino Labs to Bring Medicinal Cannabis Oil to Mexico
Joint venture secures PharmaCielo's foothold in world's largest legalized medicinal cannabis marketplace with population of 130-million and over 33,0001medicinal distribution points Marks key step in PharmaCielo's plan to become a leading global exporter of medicinal-grade cannabis oils and derivative products and in bringing economic value to individual global markets TORONTO and MEXICO CITY, MEXICO, Jan. 28, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCi
Jan 18, 2019 09:40 am ET
PharmaCielo Ltd. Opens the Market
TORONTO, Jan. 18, 2019 /CNW/ - Simon Langelier, Chairman of the Board, PharmaCielo Ltd. (PCLO), joined Tim Babcock, Managing Director, Capital Formation, TSX Venture Exchange, to open the market. PharmaCielo is headquartered in Canada, with a focus on processing and supplying medicinal-grade cannabis oil extracts and related products to large channel distributors. PharmaCielo's principal, and wholly owned subsidiary is PharmaCielo Holdings, headquartered at its nursery and propagation centre located in Rionegro, Colombia. PharmaCielo Ltd. commenced trading on TSX Venture Exchange on January
Jan 18, 2019 06:50 am ET
PharmaCielo Begins Trading on the TSX Venture Exchange Under Ticker PCLO
PharmaCielo to begin trading on the TSX Venture Exchange ("TSXV" or "TSX Venture") under the Ticker PCLO at market open today, January 18, 2019. In the process of scaling its area under current cultivation from 5.3 hectares of open-air greenhouse (~570,487 ft2) to approximately 20 hectares (~2.15 million ft2) by the end of 2019. Approximately 139 hectares (~15 million feet2) of total cultivation capacity, currently. Currently producing medicinal grade CBD- and THC-dominant cannabis oil extracts in a temporary facility. Expects to complete construction of its 2,300 m2 (24,757 ft2) GMP2 certif
Jan 17, 2019 03:44 pm ET
IIROC Trading Resumption - PCLO; BZ; GCX
VANCOUVER, Jan. 17, 2019 /CNW/ - Trading resumes in:
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.